Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Podobne zapisy

• Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
  od: Andrew Blumenfeld, i wsp.
  Wydane: (2022-07-01)
• Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
  od: Timothy R. Smith, i wsp.
  Wydane: (2021-11-01)
• Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
  od: Dawn C. Buse, i wsp.
  Wydane: (2022-02-01)
• Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
  od: Peter McAllister, i wsp.
  Wydane: (2022-02-01)
• Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
  od: Roger Cady, i wsp.
  Wydane: (2022-07-01)